Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Rangering i aksjer #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Aksjekurs
$206.50
Markedsverdi
$365.13B
Endring (1 dag)
-0.31%
Endring (1 år)
2.58%
Land
US
Handel AbbVie Inc. (ABBV)

Kategori

EPS for AbbVie Inc. (ABBV)
EPS per December 2025 TTM: $2.37
Ifølge de siste økonomiske rapportene og aksjekursen til AbbVie Inc. er selskapets nåværende EPS (TTM) $2.37. Ved slutten av 2024 hadde selskapet en EPS på $2.40, en nedgang sammenlignet med EPS-en i 2023 som var $2.73.
EPS-historikk for AbbVie Inc. fra 2009 til 2026
EPS ved slutten av hvert år
År EPS Endre
2026 (TTM) $2.37 -0.42%
2025 $2.38 -0.83%
2024 $2.40 -12.09%
2023 $2.73 -58.95%
2022 $6.65 2.62%
2021 $6.48 137.36%
2020 $2.73 -48.49%
2019 $5.30 43.63%
2018 $3.69 11.48%
2017 $3.31 -9.32%
2016 $3.65 15.87%
2015 $3.15 183.78%
2014 $1.11 -56.98%
2013 $2.58 -22.99%
2012 $3.35 58.02%
2011 $2.12 -18.15%
2010 $2.59 -9.76%
2009 $2.87 0.00%
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$23.00 870.46%
US
$13.20 456.96%
GB
$11.10 368.35%
US
$7.20 203.80%
CH
$7.30 208.02%
US